A Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome

ID Number 11-1373

Principal Investigator(s)
Alexander Kolevzon

Department(s) or Division(s)


This study examines the efficacy, safety and tolerability of STX209 (arbaclofen) on social motivation in subjects with Fragile X syndrome. It is hypothesized that STX209 will be associated with improvement in social withdrawal in subjects with Fragile X syndrome. All subjects will receive 12 weeks of treatment with STX209 or placebo in a double-blind, placebo-controlled, parallel group study design. The 12-week treatment period will be followed by treatment with active medication.

Contact Information
Lauren Bush
(212) 241-2826

Recruiting Patients: Yes